APA

Ahlgren G. M., Flodgren P., Tammela T. L. J., Kellokumpu-Lehtinen P., Borre M., Angelsen A., Iversen J. R., Sverrisdottir A., Jonsson E. & Sengelov L. (20190314). Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. : European urology.

Chicago

Ahlgren Göran M, Flodgren Per, Tammela Teuvo L J, Kellokumpu-Lehtinen Pirkko, Borre Michael, Angelsen Anders, Iversen Jon Reidar, Sverrisdottir Asgerdur, Jonsson Eirikur and Sengelov Lisa. 20190314. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. : European urology.

Harvard

Ahlgren G. M., Flodgren P., Tammela T. L. J., Kellokumpu-Lehtinen P., Borre M., Angelsen A., Iversen J. R., Sverrisdottir A., Jonsson E. and Sengelov L. (20190314). Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. : European urology.

MLA

Ahlgren Göran M, Flodgren Per, Tammela Teuvo L J, Kellokumpu-Lehtinen Pirkko, Borre Michael, Angelsen Anders, Iversen Jon Reidar, Sverrisdottir Asgerdur, Jonsson Eirikur and Sengelov Lisa. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. : European urology. 20190314.